Ensitrelvir for the treatment of COVID-19: Final analysis of a post-marketing surveillance from Japan
This PMS including >3000 patients suggested the safety of ensitrelvir for the treatment of patients with COVID-19 in Japan, with no new safety concern.
Authors
- Eri Tsukimura
- Eriko Ogura (ORCID: https://orcid.org/0000-0002-9671-8572)
- Noriko Hayashi (ORCID: https://orcid.org/0000-0001-5346-9193)
Institutions
- Shionogi (Japan) (JP)
- Futaba (Japan) (JP)
Publication Details
- Journal
- Journal of Infection and Chemotherapy
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1016/j.jiac.2024.12.003
- Citations
- 3
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- Shionogi